[1] Fu P P, Xia Q, Lin G, et al.Pyrrolizidine Alkaloids-Genotoxicity, Metabolism Enzymes, Metabolic Activation, and Mechanisms[J]. Drug Metabolism Reviews, 2004, 36(1):1-55. [2] Yang Y C, Crowder J, Wardle N J, et al.1H NMR study of monocrotaline and its metabolites in human blood[J]. Food Chem Toxicol., 2011,49(11):2793-2799. [3] The China Pharmacopoeia Committee. Pharmacopoeia of the People's Republic of China(in Chinese)[S]. 2015ed. Beijing: China Medical Science Press, 2015. [4] Ruan J, Yang M, Fu P, et al.Metabolic Activation of Pyrrolizidine Alkaloids: Insights into the Structural and Enzymatic Basis[J]. Chem Res Toxicol., 2014,27(16):1030-1039. [5] Lu Y, Ma J, Song Z, et al.The role of formation of pyrrole-ATP synthase subunit beta adduct in pyrrolizidine alkaloid-induced hepatotoxicity[J]. Archives of Toxicology, 2018,92(11):3403-3414. [6] Kolrep F, Numata J, Kneuer C, et al.In vitro biotransformation of pyrrolizidine alkaloids in different species. Part I: Microsomal degradation[J]. Archives of Toxicology, 2018,92(3):1089-1097. [7] Li X, Yang X, Xiang E, et al.Maternal-Fetal Disposition and Metabolism of Retrorsine in Pregnant Rats[J]. Drug Metabolism and Disposition, 2018, 46(4):422-428. [8] Guo Y, Ma Z, Kou H, et al.Synergistic effects of pyrrolizidine alkaloids and lipopolysaccharide on preterm delivery and intrauterine fetal death in mice[J]. Toxicology Letters, 2013, 221(3):212-218. [9] Kalisch-Smith J I, Simmons D G, Dickinson H, et al. Review: Sexual dimorphism in the formation, function and adaptation of the placenta[J]. Placenta, 2017,54:10-16. [10] Mattocks A R, Legg R F, Jukes R.Trapping of short-lived electrophilic metabolites of pyrrolizidine alkaloids escaping from perfused rat liver[J]. Toxicology Letters, 1990, 54(1):93-99. [11] Cooper R A, Huxtable R J.The relationship between reactivity of metabolites of pyrrolizidine alkaloids and extrahepatic toxicity[J]. Proceedings of the Western Pharmacology Society, 1999, 42:13-16. [12] Hakkola J, Pasanen M, Hukkanen J, et al.Expression of xenobiotic-metabolizing cytochrome P450 Forms in human full-term placenta[J]. Biochemical Pharmacology, 1996, 51(4):403-411. [13] Staud F, Cerveny L, Ceckova M.Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure[J]. Journal of Drug Targeting, 20(9):736-763. [14] Tu M, Li L, Lei H, et al.Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity[J]. Toxicology, 2014, 322:34-42. [15] Hessel S, Gottschalk C, Schumann D, et al.Structure-activity relationship in the passage of different pyrrolizidine alkaloids through the gastrointestinal barrier: ABCB1 excretes heliotrine and echimidine[J]. Molecular Nutrition & Food Research, 2014, 58(5):995-1004. [16] Longo L D, Reynolds L P.Some historical aspects of understanding placental development, structure and function[J]. International Journal of Developmental Biology, 2010,54(2-3):237-55. [17] DuyguIskenderMazman, Zuhal Akçören, Şule Yiğit, et al. Placental findings of IUGR and non-IUGR[J]. Turk J Pediatr, 2014, 56(4):368-373. [18] Medeiros R M T, Silvana L. Górniak, José Luis Guerra. Fetotoxicity and reproductive effects of monocrotaline in pregnant rats[J]. Journal of Ethnopharmacology, 2000, 69(2):181-188. [19] Orhan H.Extrahepatic targets and cellular reactivity of drug metabolites[J]. Curr Med Chem, 2015,22(4):408-437. [20] Lee N, Hebert M F, Prasad B, et al.Effect of Gestational Age on mRNA and Protein Expression of Polyspecific Organic Cation Transporters during Pregnancy[J]. Drug Metabolism and Disposition, 2013, 41(12):2225-2232. |